Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
BACKGROUND
Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI.


RESULTS
We studied 13 608 patients with acute coronary syndrome undergoing percutaneous coronary intervention randomized to prasugrel or clopidogrel and treated for 6 to 15 months in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). Each MI underwent supplemental classification as spontaneous, secondary, or sudden cardiac death (types 1, 2, and 3) or procedure related (Types 4 and 5) and examined events occurring early and after 30 days. Prasugrel significantly reduced the overall risk of MI (7.4% versus 9.7%; hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.67 to 0.85; P<0.0001). This benefit was present for procedure-related MIs (4.9% versus 6.4%; HR, 0.76; 95% CI, 0.66 to 0.88; P=0.0002) and nonprocedural (type 1, 2, or 3) MIs (2.8% versus 3.7%; HR, 0.72; 95% CI, 0.59 to 0.88; P=0.0013) and consistently across MI size, including MIs with a biomarker peak > or =5 times the reference limit (HR. 0.74; 95% CI, 0.64 to 0.86; P=0.0001). In landmark analyses starting at 30 days, patients treated with prasugrel had a lower risk of any MI (2.9% versus 3.7%; HR, 0.77; P=0.014), including nonprocedural MI (2.3% versus 3.1%; HR, 0.74; 95% CI, 0.60 to 0.92; P=0.0069).


CONCLUSIONS
Treatment with prasugrel compared with clopidogrel for up to 15 months in patients with acute coronary syndrome undergoing percutaneous coronary intervention significantly reduces the risk of MIs that are procedure related and spontaneous and those that are small and large, including new MIs occurring during maintenance therapy.
Morrow
David A
DA
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. dmorrow@partners.org
Wiviott
Stephen D
SD
White
Harvey D
HD
Nicolau
Jose C
JC
Bramucci
Ezio
E
Murphy
Sabina A
SA
Bonaca
Marc P
MP
Ruff
Christian T
CT
Scirica
Benjamin M
BM
McCabe
Carolyn H
CH
Antman
Elliott M
EM
Braunwald
Eugene
E
D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000628:therapy; D000789:Angina, Unstable / Q000188:drug therapy / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D015415:Biomarkers; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D052279:Creatine Kinase, MB Form / Q000097:blood; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000517:prevention & control; D004311:Double-Blind Method; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D009203:Myocardial Infarction / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D010879:Piperazines / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D012008:Recurrence; D013876:Thiophenes / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D020107:Troponin T / Q000097:blood
D015415:Biomarkers; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D020107:Troponin T; D000077144:Clopidogrel; D052279:Creatine Kinase, MB Form; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine